Connect with us

Health

Commission opens disparagement investigation into Sanofi

SHARE:

Published

3 weeks ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Commission has opened a formal investigation into possible anticompetitive conduct by Sanofi for disparaging a competitor’s flu vaccine intended for vulnerable patient groups.

Sanofi’s ‘Efluelda’ and CSL Seqirus’s ‘Fluad’ enhanced flu vaccine are specifically designed to provide greater protection against influenza for people over 60.

The Commission claims that Sanofi pursued a misleading communication campaign targeting healthcare professionals in Germany and France, suggesting that the evidentiary basis for Fluad was weaker than for its vaccine. This contradicted the findings of the European Centre for Disease Control (ECDC) and national immunisation technical advisory groups in Germany and France.

A Sanofi spokesperson told Vital Signs that they may address the Commission's concerns through commitments. Adding that Sanofi...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending